Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
Richette
Pascal
P
Department of Rhumatology, Hôpital Lariboisière, Paris, France. pascal.richette@lrb.aphp.fr
Viguier
Manuelle
M
Bachelez
Hervé
H
Bardin
Thomas
T
D000287:Administration, Topical; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001168:Arthritis / Q000150:complications / Q000188:drug therapy; D003875:Drug Eruptions; D000068800:Etanercept; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D012882:Skin Tests; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D028761:Withholding Treatment
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept